Halozyme Therapeutics, Inc. (HALO)
Automate Your Wheel Strategy on HALO
With Tiblio's Option Bot, you can configure your own wheel strategy including HALO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HALO
- Rev/Share 9.7136
- Book/Share 2.7422
- PB 26.5953
- Debt/Equity 4.5353
- CurrentRatio 8.3606
- ROIC 0.2863
- MktCap 8530330380.0
- FreeCF/Share 4.4559
- PFCF 15.7767
- PE 15.8799
- Debt/Assets 0.7347
- DivYield 0
- ROE 1.3663
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | HALO | Morgan Stanley | Equal Weight | Overweight | -- | $75 | Aug. 6, 2025 |
| Resumed | HALO | Goldman | -- | Neutral | -- | $55 | July 10, 2025 |
| Downgrade | HALO | Morgan Stanley | Overweight | Equal Weight | -- | $62 | May 14, 2025 |
| Downgrade | HALO | Leerink Partners | Market Perform | Underperform | -- | $47 | May 13, 2025 |
| Downgrade | HALO | Wells Fargo | Overweight | Equal Weight | $58 | $62 | Oct. 7, 2024 |
| Downgrade | HALO | JP Morgan | Overweight | Neutral | $52 | $57 | Sept. 19, 2024 |
News
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics, Inc. (HALO) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HALO's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.
Read More
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
Published: July 23, 2025 by: PRNewsWire
Sentiment: Neutral
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma SAN DIEGO , July 23, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval of a new indication for DARZALEX Faspro® (daratumumab) co-formulated with ENHANZE®, as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma. "This approval reinforces DARZALEX Faspro with ENHANZE as a foundational treatment across all stages of multiple myeloma," said Dr. Helen …
Read More
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: June 20, 2025 by: PRNewsWire
Sentiment: Neutral
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO , June 20, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. VYVGART is the first and only targeted IgG Fc-antibody …
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Read More
4 Stocks With Strong Interest Coverage Ratios to Buy in June 2025
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
STRL, BJ, MOH, and HALO shine with strong interest coverage ratios, signaling solid fundamentals for June 2025.
Read More
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
4 Stocks With Impressive Interest Coverage Ratio to Buy Now
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
STRL, AXS, MOH & HALO's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Read More
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Read More
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Halozyme Therapeutics reported strong Q1 2025 earnings with a 35% revenue increase, 54% net income growth, and raised full-year guidance, reinforcing its status as a top biotech growth story. Key growth drivers include the ENHANZE portfolio with new blockbuster drugs, a robust clinical pipeline, and next-gen delivery systems, ensuring sustained royalty growth and competitive advantage. Despite potential risks like the Keytruda SC litigation and pharma tariffs, Halozyme's strong balance sheet, rising free cash flow, and share buybacks boost EPS and shareholder value.
Read More
Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025.
Read More
Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communications Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Sadia Rahman - Wells Fargo Sean Laaman - Morgan Stanley Michael DiFiore - Evercore ISI Mitchell Kapoor - H.C. Wainwright Brendan Smith - TD Cowen David Risinger - Leerink Partners Operator Good afternoon.
Read More
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.79 per share a year ago.
Read More
Halozyme Therapeutics: Still Undervalued Ahead Of Earnings
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Positive
Halozyme Therapeutics, Inc. remains a buy due to its strong subscription-based business model, high growth, and undervaluation. HALO's robust product library, focused on drug delivery systems, positions it well to avoid sector issues and continue outperforming the market. The company has shown consistent revenue growth, high gross margins, and strong returns on investments, with a fair value estimated at $67.71.
Read More
Halozyme to Report First Quarter 2025 Financial and Operating Results
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m.
Read More
About Halozyme Therapeutics, Inc. (HALO)
- IPO Date 2004-03-16
- Website https://www.halozyme.com
- Industry Biotechnology
- CEO Helen I. Torley M.B. Ch. B., M.R.C.P.
- Employees 350